Current Report Filing (8-k)
27 November 2014 - 12:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
November 26, 2014
Date of Report (Date of Earliest
Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
000-31187 |
870638336 |
(State or other jurisdiction of |
(Commission File |
(IRS Employer Identification |
incorporation) |
Number) |
No.) |
6425
Abrams, Ville St- Laurent, Quebec, Canada |
H4S 1X9 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code: (514)
331-7440
Check the appropriate box below if the Form 8K fining is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communication pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx Announces Update to Settlement of U.S. Patent
Litigation Related to Forfivo XL®
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INTELGENX TECHNOLOGIES CORP.
|
|
|
|
|
Dated: November 26, 2014 |
By: /s/ Paul A.
Simmons
|
|
Paul A. Simmons |
|
Chief Financial Officer
|
Exhibit 99.1
IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL®
Saint Laurent, Quebec - November 26, 2014 - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL® 450 mg tablets.
Under the terms of the settlement, Wockhardt has been granted the rights, with effect from January 15, 2018, to be the exclusive marketer and distributor of an authorized generic of Forfivo XL® in the U.S.
The Company will hold a call to discuss the settlement on Wednesday, December 3, 2014 at 10:00 AM ET. A live broadcast of the call will be available through the Company's website at
www.intelgenx.com. Following the live call, a replay will be
available on the Company's website, www.intelgenx.com, under "Investor Relations".
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: IntelGenx Management Update Call
Webcast Registration: CLICK HERE
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of
active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films.
IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as
animal health products. More information is available about the company at
www.intelgenx.com.
Investor Contact:
COCKRELL GROUP
T: 877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Company Contact:
Paul A. Simmons
Chief Financial Officer
IntelGenx Technologies Corp.
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Apr 2024 to May 2024
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From May 2023 to May 2024